Alexander J Szubert
Overview
Explore the profile of Alexander J Szubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White I, Szubert A, Choodari-Oskooei B, Walker A, Parmar M
Clin Trials
. 2023 Oct;
21(2):162-170.
PMID: 37904490
Background: A 2×2 factorial design evaluates two interventions (A versus control and B versus control) by randomising to control, A-only, B-only or both A and B together. Extended factorial designs...
2.
Waalewijn H, Szubert A, Wasmann R, Wiesner L, Chabala C, Bwakura-Dangarembizi M, et al.
Clin Infect Dis
. 2023 Jun;
77(6):875-882.
PMID: 37315296
Background: We evaluated the pharmacokinetics of tenofovir alafenamide fumarate (TAF) and tenofovir in a subset of African children enrolled in the CHAPAS-4 trial. Methods: Children aged 3-15 years with human...
3.
Bevers L, Waalewijn H, Szubert A, Chabala C, Bwakura-Dangarembizi M, Makumbi S, et al.
Clin Infect Dis
. 2023 Jun;
77(9):1312-1317.
PMID: 37280040
Background: Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse transcriptase inhibitors, is currently the preferred first-line treatment for human immunodeficiency virus (HIV) in childhood. CHAPAS4 is an ongoing...
4.
Pollock K, Cheeseman H, Szubert A, Libri V, Boffito M, Owen D, et al.
EClinicalMedicine
. 2022 Jan;
44:101262.
PMID: 35043093
Background: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel technology formulated as a low dose vaccine against COVID-19. Methods: A phase I first-in-human dose-ranging trial of a saRNA...
5.
Prendergast A, Szubert A, Pimundu G, Berejena C, Pala P, Shonhai A, et al.
AIDS
. 2021 Jul;
35(10):1537-1548.
PMID: 34270487
Objective: To determine the impact of virological control on inflammation and cluster of differentiation 4 depletion among HIV-infected children initiating antiretroviral therapy (ART) in sub-Saharan Africa. Design: Longitudinal cohort study....
6.
Prendergast A, Berejena C, Pimundu G, Shonhai A, Bwakura-Dangarembizi M, Musiime V, et al.
AIDS
. 2019 Apr;
33(9):1485-1490.
PMID: 31008797
Objectives: A proportion of HIV-infected children with advanced disease develop severe malnutrition soon after antiretroviral therapy (ART) initiation. We tested the hypothesis that systemic inflammation underlies the pathogenesis of severe...
7.
Bourke C, Gough E, Pimundu G, Shonhai A, Berejena C, Terry L, et al.
Sci Transl Med
. 2019 Apr;
11(486).
PMID: 30944164
Long-term cotrimoxazole prophylaxis reduces mortality and morbidity in HIV infection, but the mechanisms underlying these clinical benefits are unclear. Here, we investigate the impact of cotrimoxazole on systemic inflammation, an...
8.
Kityo C, Szubert A, Siika A, Heyderman R, Bwakura-Dangarembizi M, Lugemwa A, et al.
PLoS Med
. 2018 Dec;
15(12):e1002706.
PMID: 30513108
Background: In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk...
9.
Mallewa J, Szubert A, Mugyenyi P, Chidziva E, Thomason M, Chepkorir P, et al.
Lancet HIV
. 2018 Apr;
5(5):e231-e240.
PMID: 29653915
Background: In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use...
10.
Post F, Szubert A, Prendergast A, Johnston V, Lyall H, Fitzgerald F, et al.
Clin Infect Dis
. 2018 Mar;
66(suppl_2):S132-S139.
PMID: 29514234
Background: In sub-Saharan Africa, 20%-25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial, a...